Literature DB >> 31929570

Vascularization and biocompatibility of poly(ε-caprolactone) fiber mats for rotator cuff tear repair.

Sarah Gniesmer1,2, Ralph Brehm3, Andrea Hoffmann2,4, Dominik de Cassan5, Henning Menzel5, Anna Lena Hoheisel2,6, Birgit Glasmacher2,6, Elmar Willbold2,7, Janin Reifenrath2,7, Nils Ludwig8, Ruediger Zimmerer1, Frank Tavassol1, Nils-Claudius Gellrich1, Andreas Kampmann1,2.   

Abstract

Rotator cuff tear is the most frequent tendon injury in the adult population. Despite current improvements in surgical techniques and the development of grafts, failure rates following tendon reconstruction remain high. New therapies, which aim to restore the topology and functionality of the interface between muscle, tendon and bone, are essentially required. One of the key factors for a successful incorporation of tissue engineered constructs is a rapid ingrowth of cells and tissues, which is dependent on a fast vascularization. The dorsal skinfold chamber model in female BALB/cJZtm mice allows the observation of microhemodynamic parameters in repeated measurements in vivo and therefore the description of the vascularization of different implant materials. In order to promote vascularization of implant material, we compared a porous polymer patch (a commercially available porous polyurethane based scaffold from Biomerix™) with electrospun polycaprolactone (PCL) fiber mats and chitosan-graft-PCL coated electrospun PCL (CS-g-PCL) fiber mats in vivo. Using intravital fluorescence microscopy microcirculatory parameters were analyzed repetitively over 14 days. Vascularization was significantly increased in CS-g-PCL fiber mats at day 14 compared to the porous polymer patch and uncoated PCL fiber mats. Furthermore CS-g-PCL fiber mats showed also a reduced activation of immune cells. Clinically, these are important findings as they indicate that the CS-g-PCL improves the formation of vascularized tissue and the ingrowth of cells into electrospun PCL scaffolds. Especially the combination of enhanced vascularization and the reduction in immune cell activation at the later time points of our study points to an improved clinical outcome after rotator cuff tear repair.

Entities:  

Year:  2020        PMID: 31929570      PMCID: PMC6957163          DOI: 10.1371/journal.pone.0227563

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Rotator cuff tears are common injuries in human shoulders. Especially degenerative processes in elderly people account for a large number of injuries, so that about 50% of people over their seventies are affected by a rotator cuff tear [1]. Depending on the extent of the tear, the symptoms include pain, reduced function and weakness. Especially lateral abduction of the affected arm causes severe pain, which persists even throughout the night while resting [2]. Frequently, changes in the musculotendinous unit occur between the onset of the rotator cuff tear and the time of diagnosis. The loss of muscle activity thereby leads to muscle atrophy and the loss of pretension entails fatty infiltration of the musculature [3,4]. As a result tendon retraction arises, as well as loss of elasticity in the musculotendinous unit [5]. These changes complicate or in some cases hinder surgical fixation of the tendon to the osseous attachment. The main problem after surgery is the healing process after tendon reconstruction, because instead of a regenerated tendon-bone-junction [6] the formation of scar tissues, which show reduced tensile strength compared to the intact tendon, can be observed [7]. For regeneration of tendon defects, different graft materials and surgical techniques were developed to support tendon healing [6], but neither special techniques nor different graft materials are able to improve the prognosis after tendon reconstruction significantly. Furthermore, also after successful refixation a reduced tendon strength compared to healthy tendons can be observed [8] and failure rates after tendon reconstruction remain unacceptably high. The high incidence of failure related to existing implant materials and repair techniques emphasize the importance of functional solutions for tendon repair [9]. Implants that facilitate an effective surgical treatment of rotator cuff tears ideally mimic the biological and biomechanical characteristics of the intact tendon and at the same time do not hinder the natural healing process. A key prerequisite for a successful implant material is the rapid ingrowth of cells and tissues for the development of a regenerated tendon-bone-transition. Ingrowth of cells and tissues thereby strongly depends on a fast vascularization of the implant material for transporting nutrients, growth factors, and supporting gas exchange and removal of waste materials. Implant failure is often attributable to insufficient tendon healing, mainly depending on insufficient vascularization [10,11]. Potential candidates to fulfill these criteria are electrospun fiber mats, which are already often used in tissue engineering applications [12]. Polycaprolactone (PCL) is applicable in this field because of its adequate mechanical properties, its biocompatibility and slow degradation in vivo [13]. However, its hydrophobic nature interferes with cell attachment and growth [14]. Recently it was shown that electrospun PCL fiber mats with a CS-g-PCL coating are more hydrophilic and provide cellular recognition sites, which create an attractive surface for initial cell attachment [15,16]. In recent decades biodegradable polymers, like PCL, have become increasingly important. PCL has a wide range of application in tissue engineering including vascular grafts [17], bone [18,19], cartilage [20], liver [21], bladder [22], skin [23] and nerve [24]. Implants for rotator cuff tear repair should have a positive impact on tendon healing by supporting cellular infiltration and guiding the regeneration of an organized tendon structure. These positive effects could be shown for nanofibrous PCL based scaffolds in an in vivo model in rats for primary rotator cuff repair [25]. Electrospun PCL fiber mats are particularly suited as an implant for rotator cuff tear repair as they can easily be produced with variable fiber arrangements. By fabrication of fiber mats with directed or undirected fiber orientation they can be adopted to the microarchitecture of the different sections of the native tendon. The specific design of the fiber mat in turn stimulates the regeneration of organized tendon structures. In a previous study we analyzed electrospun PCL fiber mats with undirected fiber orientation, that were intended to mimic the specific fiber orientation at the tendon-bone transition in the femur chamber in rats [26]. In this study fiber mats with directed fiber structures were used to simulate the tendon-muscle transition. These electrospun PCL fiber mats are intended to form the lead structure for the transition zone of the rotator cuff. Different studies investigated the physical, chemical and biological characteristics of scaffold devices for rotator cuff repair [27], but data describing the vascularization of electrospun PCL fiber mats are limited. For characterization of the early vascularization of electrospun PCL implant materials the dorsal skinfold chamber in mice was used in the present study. This in vivo model allows the repetitive observation of the vascularization of different implant materials by means of intravital fluorescence microscopy [28]. The aim of this study was to compare microhemodynamic parameters inside electrospun PCL based implants as described above with the microhemodynamic parameters of a reticulated polyurethane based scaffold (Biomerix™, Biomerix Corporation, Fremont, CA), which was used in studies for rotator cuff repair before [29].

Materials and methods

Implants

Electrospun polycaprolactone fiber mats with aligned fibers were produced as described elsewhere [30]. Briefly, a poly-ε-caprolactone solution of 170 mg/ml (Mn = 80.000 g/mol, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) (PCL) and trifluoroethanol (TFE, abcr GmbH, Karlsruhe, Germany) was used to produce electrospun PCL fiber mats. The scaffolds were produced with a collector speed of 8 m/s, which resulted in orientated fibers. The voltage was set to 25 kV and the emitter to collector distance to 25 cm. By using a flow rate of 4 ml/h 8 ml polymer solution resulting in fiber mats with a thickness of approximately 200 μm. Experimental groups were unmodified PCL fiber mats and PCL fiber mats modified with a fiber coating utilizing a graft copolymer consisting of chitosan and polycaprolactone, called CS-g-PCL [31]. As a control group a commercially available porous polyurethane based scaffold (Biomerix RCR Patch, Biomerix Corporation, Somerset, USA; purchased from Cellon, Bascharage, Luxembourg), was used [29,32]. For sterilization all implants were cut into pieces of 3 mm x 5 mm and shrink-wrapped in sterilization pouches (SteriClin, Vereinigte Papierwarenfabriken, Feuchtwangen, Germany). Sterilization was performed by beta radiation with a dose of 25 kGy (using a Rhodotron TT 100 e-beam accelerator, Mediscan, Kremsmünster, Austria).

Evaluation of porosity and pore diameter

Gravimetric method was used to determine the porosity of the fibrous scaffolds by using the mass, density and dimensions of a sample. The pore diameter was determined with a capillary flow porometer (3 Gzh, Quantachrome GmbH & Co.KG). This characterization technique based on the displacement of a wetting liquid (Porofil®, Quantachrome GmbH & Co. KG) from the pores of the sample by increasing the pressure from an inert gas. The underlying equations for the calculation of the porosity and the pore diameter were described elsewhere [26]. The porosity and the pore diameter of the reticulated polyurethane based scaffold was evaluated in a previous study [26].

Experimental protocol

For intravital fluorescence microscopy, a total of 24 BALB/cJZtm mice were equipped with dorsal skinfold chambers. Scaffolds, consisting of either porous polymer patch (control) (n = 8) or unmodified PCL fiber mats (n = 7) or chitosan coated PCL fiber mats (n = 9), were implanted into the dorsal skinfold chamber. Intravital fluorescence microscopy analysis of volumetric blood flow, wall shear rate, leukocyte-endothelial cell interaction, macromolecular leakage and functional capillary density were performed immediately as well as 3, 6, 10 and 14 days after implantation.

Animals

All experiments were conducted in accordance with the German legislation for the protection of animals and the Guide for the Care and Use of Laboratory Animals (8th edition, 2011). The experiments were approved by the competent authority (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, reference number 33.12-42502-04-15/2015). Female BALB/cJZtm mice (Central animal facility, Hannover Medical School) with an age of 12 to 18 weeks and a body weight of 22.5 g ± 1.9 g were used for the study. All animals were housed individually per cage at room temperature between 22°C and 24°C and a relative humidity of 60–65% with a 12-hour day-night cycle. The mice had free access to tap water and standard pellet food (1328 Hybridpellet, Altromin, Lage, Germany) at all times.

Anesthesia

The preparation of the dorsal skinfold chamber and repeated intravital fluorescence microscopy were executed under inhalational anesthesia (EZ-7000 Classic System, PLEXX, Elst, The Netherlands) by isoflurane (Isofluran CP®, cp pharma, Burgdorf, Germany). After the animals were placed in an induction chamber anesthesia was induced with 5% isoflurane until loss of righting reflex. The anesthesia depth was determined with the aid of the toe pinch. After induction the animals were placed in appropriate position on a heating mat to protect them against hypothermia. Animals remained anesthetized with the aid of a nose cone with 2–3% isoflurane in oxygen.

Preparation of the dorsal skinfold chamber

The dorsal skinfold chamber in mice is an accepted model to investigate changes of the microcirculation and the biocompatibility of a given material [33]. The chamber is constructed of two symmetrical frames and has an observation window with 12 mm diameter (Fig 1). The preparation of the dorsal skinfold chamber has been described in detail previously [34,35]. Briefly, after preparation of the skin the frames were implanted on the extended dorsal skinfold of the mice, so that the skin was double-layered between the frames. One layer of skin including cutis, subcutis, musculus panniculus carnosus, and the two layers of the musculus retractor was completely removed by dissection in a circular area with a diameter of 12 mm, exposing the musculus panniculus carnosus of the opposite skin layer. The exposed tissue layer was covered with a coverslip that was secured with a circlip. Postoperatively, the animals were given three days for convalescence and adaption to the dorsal skinfold chamber before the implant material was tested in vivo. For implantation the coverslip was removed and the implant material was inserted in the center of the observation window. The mice were treated with antibiotics (Enrofloxacin 5 mg/kg, Baytril 25 mg/ml, Bayer, Leverkusen, Germany) intraoperatively and per os for seven days after surgery. Analgesics (Carprofen, 5 mg/kg, Rimadyl 50 mg/ml, Pfizer Deutschland GmbH, Berlin, Germany) were given intraoperatively and for two days after surgery. During the experimental period the animals were evaluated daily with a score based evaluation system including the assessment of weight loss, general condition, spontaneous behavior, clinical findings and lameness.
Fig 1

Dorsal skinfold chamber.

Two symmetrical steel frames are connected via screws with a gap nut in between. The observation window (Ø 12 mm) is covered with a coverslip, which is fixed by a circlip. Recesses reduce the weight of the chamber.

Dorsal skinfold chamber.

Two symmetrical steel frames are connected via screws with a gap nut in between. The observation window (Ø 12 mm) is covered with a coverslip, which is fixed by a circlip. Recesses reduce the weight of the chamber.

Intravital fluorescence microscopy and analysis of microcirculatory parameters

Intravital fluorescence microscopy was performed as described in Gniesmer et al., 2019 [26]. The recorded data was analyzed using the image analysis software CapImage (CapImage 8.6.3, Zeintl, Heidelberg, Germany). Briefly leukocyte-endothelial cell interactions, microhemodynamics, and macromolecular leakage were measured in four different regions of interest in the border zone of the scaffold. In each region of interest one venule in the granulation tissue around the implant (inner diameter: 20–40 μm) was selected and observed over 20 seconds for evaluation of vessel diameter, red blood cell velocity, wall shear rate and macromolecular leakage. The leukocytes were classified according to their interaction with the vascular endothelium as adherent (they that did not move or detach from the endothelial lining within an observation period of 20 s), rolling (moving cells with a velocity less than two-fifth of the centerline velocity) or free flowing cells. Microvessel density, defined as the length of blood vessels per area of observation given in cm/cm2, was measured in the periphery around the implant and in the center of the implant. Both values were displayed as the total functional capillary density expressed as the sum of peripheral and central functional capillary density. For a full description of the data analysis refer to Gniesmer et al., 2019 [26].

Histology and immunohistochemistry

After the experimental period of 14 days, animals were finalized via cervical dislocation under deep anesthesia and histological examinations were performed. Formalin-fixed specimens of the dorsal skinfold chamber were embedded in paraffin for light microscopy according to standard procedures. Thin sections (5 μm) were stained with hematoxylin (Merck KGaA, Darmstadt, Germany) and eosin (Merck KGaA, Darmstadt, Germany) according to standard procedures and examined by light microscopy (Leica DM4000 B, Leica Mikrosysteme, Wetzlar, Germany). Van Gieson staining of thin sections (5 μm) with hematoxylin and picrofuchsia acid solution (Merck KGaA, Darmstadt, Germany) according to standard procedures was applied to detect collagen fibers. All specimens were examined by light microscopy (Leica DM4000 B, Leica Mikrosysteme, Wetzlar, Germany). For detection of capillaries, endothelial cells were immunohistochemically stained using a rabbit anti-mouse CD31 antibody (LifeSpan Biosciences, Seattle, USA purchased from BIOZOL Diagnostica Vertrieb GmbH, Eching, Germany); a rat anti-mouse CD68 antibody (Acris Antibodies GmbH, Herford, Germany) was used to detect macrophages; a rabbit anti-mouse CSF1R antibody (OriGene Technologies, Inc., Rockville, USA) was used for detection of macrophages in general; a rat anti-mouse CD86 antibody (OriGene Technologies, Inc., Rockville, USA) was used to detect macrophages with predominantly pro-inflammatory actions; a rabbit anti-mouse CD11b antibody (OriGene Technologies, Inc., Rockville, USA) was used to detect monocytes and a rat anti-mouse CD3 antibody (OriGene Technologies, Rockville, Inc., USA) was used to detect T-cells. As secondary antibodies a biotin conjugated goat anti-rabbit antibody and a biotin conjugated goat anti-rat antibody (both from Dianova, Hamburg, Germany), respectively were used. After incubation with streptavidin conjugated horseradish peroxidase (Dianova, Hamburg, Germany) color development with the addition of 3.3´-diaminobenzidine (DAB) (Vector Laboratories, Inc., Burlingame, CA, USA) was monitored microscopically followed by counterstaining with hematoxylin. For immunofluorescence detection an Alexa Fluor® 488-conjugated goat anti-rat antibody and an Alexa Fluor® 488-conjugated goat anti-rabbit antibody (both Dianova, Hamburg, Germany), respectively was used. Nuclei were stained using DAPI (Carl Roth GmbH, Karlsruhe, Germany). By omitting the primary antibody negative controls were performed, which all showed no detectable staining. All specimens were examined by fluorescence microscopy (Leica DM4000 B, Leica Mikrosysteme, Wetzlar, Germany). The software celISens Dimensions 1.14 (Olympus Deutschland GmbH, Hamburg, Germany) was used to quantify the immunofluorescence detection of macrophages, monocytes and T-cells. Using a magnification of 20x the area of green fluorescence was measured and normalized using the area of blue fluorescence (nuclei). Neutrophilic granulocytes were detected by naphtol-AS-D-chloroacetate esterase staining as described in Willbold et al., 2013 [36].

Statistics

Results are expressed as means ± standard error of the mean (SEM). Differences between groups were assessed by one-way analysis of variance (ANOVA) and differences within groups were analyzed by one-way repeated measures ANOVA. To identify differences between pairs of groups, Student-Newman-Keuls post-hoc tests were performed. Differences were considered significant at p < 0.05. All data were analyzed using the GraphPad Prism software (Version 7.0).

Results

Properties of the material

To compare and evaluate them towards the desired biological performance the porosity and the pore diameter of the various implant materials were examined (Fig 2). The control polyurethane material exhibited very large pore sizes of up to 175.34 μm and a porosity of 94.7% [26]. It was found that the pure PCL had a porosity of 93.67%. The pore size (maximum diameter 11.5 μm) was significantly lower than for the control group. Coating with the graft-copolymer CS-g-PCL reduced the porosity to 81.79% and simultaneously increased the fiber diameter by 0.45 μm, resulting in a maximum pore diameter of 7.56 μm (Table 1).
Fig 2

Scanning electron microscopy of the implant materials.

Porous polymer patch (A), unmodified PCL fiber mat (B) and PCL fiber mat modified with CS-g-PCL (C). Scale bars: 200 μm (A), 100 μm (B, C).

Table 1

Fiber diameter in μm, porosity in %, the maximum pore diameter in μm, the middle pore diameter in μm and the smallest pore diameter in μm of the control group scaffold (control; see Gniesmer et al., 2019), the unmodified PCL fiber mat group (PCL) and the PCL fiber mat modified with CS-g-PCL group.

controlPCLCS-g-PCL
fiber diameter-1.6 μm ± 0.7 μm2.1 μm ± 0.6 μm
porosity94.7%93.7%81.8%
Maximum pore diameter175.3 μm11.5 μm7.6 μm
Middle pore diameter139.4 μm7.5 μm5.7 μm
Smallest pore diameter78.1 μm6.1 μm4.0 μm

Scanning electron microscopy of the implant materials.

Porous polymer patch (A), unmodified PCL fiber mat (B) and PCL fiber mat modified with CS-g-PCL (C). Scale bars: 200 μm (A), 100 μm (B, C). The animals tolerated the chamber well and showed no signs of discomfort or changes in behavior. The control group and the group with CS-g-PCL lost three animals each. The reasons for the losses were very different. In the control group, one animal each was lost due to anesthesia complications, through weight loss as well as through an injury in cage. In the CS-g-PCL group, there were losses within the anesthesia, due to an inflammation at the chamber as well as due to a necrosis of tail tip. There were no losses in the group with PCL. The lost animals were not included in the statistical evaluation.

Microhemodynamic parameters

Overall, data indicated that the microvascular blood flow of host tissue was not impaired upon implantation of the different materials. Venular diameters stayed constant in all experimental groups ranging between 19 and 26 μm (Table 2). Volumetric blood flow and wall shear rates of venules were not significantly altered (Table 2).
Table 2

Venular diameters in μm, volumetric blood flow in pl/s and wall shear rate in s-1 of postcapillary and collecting venules at the border zones of the control group scaffold (control), the unmodified PCL fiber mat group (PCL) and PCL fiber mat modified with CS-g-PCL group immediately (d0) and 3, 6, 10 and 14 days after implantation.

Values are expressed as means ± SEM.

Day 0Day 3Day 6Day 10Day 14
Diameter [μm]
control24.0 ± 1.125.3 ± 1.224.7 ± 4.321.8 ± 3.726.0 ± 2.3
PCL21.7 ± 1.522.2 ± 1.121.6 ± 1.018.9 ± 1.119.8 ± 1.4
CS-g-PCL24.5 ± 1.823.3 ± 1.223.5 ± 2.321.3 ± 0.919.3 ± 1.5
Shear rate [s-1]
control60.3 ± 9.568.2 ± 9.441.4 ± 5.453.8 ± 6.556.9 ± 12.2
PCL80.0 ± 14.575.0 ± 11.972.5 ± 12.783.6 ± 6.583.3 ± 9.3
CS-g-PCL67.4 ± 8.489.9 ± 15.174.7 ± 11.1100.5 ± 10.0112.1 ± 26.0
Volumetric blood flow [pl/s]
control49.8 ± 6.259.5 ± 13.343.4 ± 10.339.6 ± 9.128.3 ± 11.2
PCL56.1 ± 13.450.9 ± 10.644.4 ± 11.336.5 ± 7.041.4 ± 9.1
CS-g-PCL69.1 ± 18.664.8 ± 8.557.0 ± 10.458.5 ± 5.150.4 ± 13.9

Venular diameters in μm, volumetric blood flow in pl/s and wall shear rate in s-1 of postcapillary and collecting venules at the border zones of the control group scaffold (control), the unmodified PCL fiber mat group (PCL) and PCL fiber mat modified with CS-g-PCL group immediately (d0) and 3, 6, 10 and 14 days after implantation.

Values are expressed as means ± SEM.

Functional capillary density

Within the first three days after implantation, all implants provoked an angiogenic response of the host striated muscle tissue. Quantitative analysis revealed a progressive increase in the group with the CS-g-PCL-coated fiber mat. At day three the angiogenic response in the control group was comparatively high, but decreased over the evaluation period. Microvascular density showed constant data in the group of unmodified fiber mats. In contrast to the control group and the unmodified fiber mat, the CS-g-PCL coated fiber mat showed significantly increased angiogenesis 14 days after implantation (Table 3, Fig 3).
Table 3

Functional capillary density in cm/cm2, number of rolling leukocytes in cells/min and number of adherent leukocytes in cells/mm2 at the periphery of the control group scaffold (control), the unmodified PCL fiber mat group (PCL) and PCL fiber mat modified with CS-g-PCL group immediately (d0) and 3, 6, 10 and 14 days after implantation.

Values are expressed as means ± SEM.

Day 0Day 3Day 6Day 10Day 14
Functional capillary density [cm/cm2]
control202.4 ± 11.1177.4 ± 33.4129.6 ± 33.2144.4 ± 35.377.5 ± 31.6
PCL85.4± 15.598.0 ± 13.991.8 ± 16.967.1 ± 8.489.0 ± 16.7
CS-g-PCL97.9 ± 13.0103.1 ± 16.693.5 ± 20.7101.0 ± 11.3148.2 ± 41.7
Number of rolling leukocytes [cells/min]
control3.6 ± 1.05.6 ± 2.15.0 ± 1.85.3 ± 2.13.8 ± 2.0
PCL5.1 ± 1.95.3 ± 2.37.8 ± 2.412.0 ± 3.415.1 ± 4.7
CS-g-PCL9.6 ± 4.311.0 ± 2.413.7 ± 3.111.2 ± 3.88.9 ± 3.8
Number of adherent leukocytes [cells/mm2]
control358.4 ± 71.9208.3 ± 44.2337.9 ± 91.4173.2 ± 73.4100.7 ± 55.8
PCL307.0 ± 97.8276.8 ± 78.3242.4 ± 122.950.0 ± 33.941.2 ± 29.8
CS-g-PCL423.5 ± 129.2360.8 ± 83.0256.9 ± 71.980.1 ± 34.137.1 ± 24.4
Fig 3

Results of intravital microscopy.

(A-C) Intravital microscopic overview images of control (A), PCL (B) and CS-g-PCL (C) at day 14. (D) Functional capillary density in cm/cm2 in the border zones of the implants 0, 3, 6, 10 and 14 days after implantation. Means ± SEM; *p < 0.05 vs. PCL and CS-g-PCL; +p < 0.05 vs. PCL on the same day;°p < 0.05 vs. CS-g-PCL on the preceding time point. Scale bars: 400 μm.

Results of intravital microscopy.

(A-C) Intravital microscopic overview images of control (A), PCL (B) and CS-g-PCL (C) at day 14. (D) Functional capillary density in cm/cm2 in the border zones of the implants 0, 3, 6, 10 and 14 days after implantation. Means ± SEM; *p < 0.05 vs. PCL and CS-g-PCL; +p < 0.05 vs. PCL on the same day;°p < 0.05 vs. CS-g-PCL on the preceding time point. Scale bars: 400 μm.

Functional capillary density in cm/cm2, number of rolling leukocytes in cells/min and number of adherent leukocytes in cells/mm2 at the periphery of the control group scaffold (control), the unmodified PCL fiber mat group (PCL) and PCL fiber mat modified with CS-g-PCL group immediately (d0) and 3, 6, 10 and 14 days after implantation.

Values are expressed as means ± SEM.

Inflammatory response

The implantation did not significantly increase the number of rolling leukocytes in all groups. The rolling leukocytes were nearly constant in the control group and the CS-g-PCL group. The PCL group showed a gradual increase of rolling leukocytes over the evaluation period. The number of adherent leukocytes at the border zones of the implants decreased over the evaluation period in all groups however, there were no significant differences detectable between the groups over the observation period (Table 3, Fig 4).
Fig 4

Leukocyte-endothelium interaction.

Leukocyte-endothelium interaction at the periphery of the implants in post-capillary and collecting venules after implantation. (A) Number of rolling leukocytes 0, 3, 6, 10 and 14 days after implantation shown as number of cells/min. The implantation of different materials did not significantly increase the number of rolling leukocytes. (B) Number of adherent leukocytes 0, 3, 6, 10 and 14 days after implantation as number of cells/mm2. The number of adherent leukocytes at the border zones of the implants decreased over the evaluation period.

Leukocyte-endothelium interaction.

Leukocyte-endothelium interaction at the periphery of the implants in post-capillary and collecting venules after implantation. (A) Number of rolling leukocytes 0, 3, 6, 10 and 14 days after implantation shown as number of cells/min. The implantation of different materials did not significantly increase the number of rolling leukocytes. (B) Number of adherent leukocytes 0, 3, 6, 10 and 14 days after implantation as number of cells/mm2. The number of adherent leukocytes at the border zones of the implants decreased over the evaluation period. Hematoxylin-eosin-staining of sections from paraffin embedded specimen at day 14 showed marked differences in cell ingrowth depending on the implant material. The porous polymer patch was well infiltrated with cells throughout all regions of the scaffold (Fig 5A). The ingrowth of cells was also detectable in specimens with PCL fiber mats, but to a lesser extent. A cell-rich layer surrounding the PCL fiber mat was conspicuous in all specimens (Fig 5B). Also in the CS-g-PCL group a cellular margin was found around the implant, but less pronounced (Fig 5C). A comparable cell-rich layer around the implant was not detectable in the control group (Fig 5A).
Fig 5

HE staining, van Gieson staining and immunohistochemical detection of CD31.

Representative histological stainings (A-I) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (A-C) HE staining (1) implant, (2) skin muscle, (3) subcutaneous tissue. (D-F) Collagen fibers were detected by van Gieson staining (arrowheads). (G-I) The presence of endothelial cells and accordingly enhanced functional capillary density was confirmed by immunohistochemical detection of CD31. (J-L) Negative controls. Areas of the implant are marked (#), arrows denote vascular structures. Scale bars: 100 μm (A—C), 50 μm (D—L).

HE staining, van Gieson staining and immunohistochemical detection of CD31.

Representative histological stainings (A-I) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (A-C) HE staining (1) implant, (2) skin muscle, (3) subcutaneous tissue. (D-F) Collagen fibers were detected by van Gieson staining (arrowheads). (G-I) The presence of endothelial cells and accordingly enhanced functional capillary density was confirmed by immunohistochemical detection of CD31. (J-L) Negative controls. Areas of the implant are marked (#), arrows denote vascular structures. Scale bars: 100 μm (A—C), 50 μm (D—L). Immunohistochemical examination with a CD31 antibody for detection of vascular structures at day 14 was applied to verify the results obtained with intravital fluorescence microscopy (Fig 5G, 5H and 5I). The granulation tissue in the border zones of the implanted materials was highly vascularized in all groups. However, endothelial cells were located in the surroundings of the PCL fiber mats (PCL and CS-g-PCL) but not within them, as compared to the control group where vascular structures were even detectable in the inside of implant structure. Negative controls for immunohistochemical detection of CD31, which showed no detectable staining, were performed by omitting the primary antibody (Fig 5J, 5K and 5L). Collagen fibers were detectable in all groups by van Gieson staining. While in the control group collagen fibers were visible around the implant structure (Fig 5D), in the groups with the PCL fiber mats (PCL and CS-g-PCL) collagen fibers could be found just as a layer underneath the implant (Fig 5E and 5F). The cellular composition of the cell-rich layer, which ensheathed the implants and the close vicinity of the implants, was further characterized by means of naphtol-AS-D-chloroacetate esterase staining and CD68 immunohistology (Fig 6). Chloroacetate-esterase positive neutrophilic granulocytes were detectable in all groups including the porous polymer patch. Although the neutrophilic granulocytes were detectable in all groups (Fig 6A, 6B and 6C), the PCL fiber mats groups, especially those with unmodified PCL (Fig 6E) showed a high infiltration of this cell type. Similar results were found by CD68 immunohistochemistry for detection of macrophages and monocytes (Fig 6D, 6E and 6F). Negative controls for immunohistochemical detection of CD68, which showed no detectable staining, were performed by omitting the primary antibody (Fig 6G, 6H and 6I).
Fig 6

Naphtol-AS-D-chloroacetate esterase staining and immunohistochemical detection of CD68.

Representative histological staining of neutrophilic granulocytes (A-C) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice using naphtol-AS-D-chloroacetate-esterase (CAE) staining. Representative histological staining for detection of macrophages and monocytes (D-I) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (D-F) Immunohistochemical detection of CD68 for detection of macrophages. (G-I) Negative controls. Areas of the implant are marked (#).

Naphtol-AS-D-chloroacetate esterase staining and immunohistochemical detection of CD68.

Representative histological staining of neutrophilic granulocytes (A-C) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice using naphtol-AS-D-chloroacetate-esterase (CAE) staining. Representative histological staining for detection of macrophages and monocytes (D-I) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (D-F) Immunohistochemical detection of CD68 for detection of macrophages. (G-I) Negative controls. Areas of the implant are marked (#). Immunofluorescence staining of the marker proteins CSF1R, CD86, CD11b and CD3 were performed to further characterize the immune response around the implant (Table 4, Fig 7). By using these markers macrophages in general, macrophages with predominantly pro-inflammatory actions, monocytes and T-cells were detectable nearly in all groups, but overall in a small extent. For all cell types, the control group showed the highest number of immune cells. We quantified and normalized the immunofluorescence signals and found significant differences for the respective immune cells. The detection of CSF1R and CD86 showed a significant lower amount of macrophages and macrophages with predominantly pro-inflammatory actions, respectively for both fiber mat groups. The detection of monocytes showed no statistically significant differences, although we found a clear lower number of this cell type in both fiber mat groups. The amount of the T-cell marker CD3 was clearly reduced in the PCL group and statistically significant reduced in the CS-g-PCL group.
Table 4

Results from quantification of immunofluorescent detection of immune cell markers.

controlPCLCS-g-PCL
CSF1R0.070 ± 0.0190.018 ± 0.0050,029 ± 0,006
CD860.086 ± 0,0200.031 ± 0.0120.035 ± 0.011
CD11b0.112 ± 0.0360.018 ± 0.0060.061 ± 0.022
CD30.072 ± 0.0250.029 ± 0.0150.020 ± 0.007
Fig 7

Immunofluorescence detection of CSF1R, CD86, CD11b and CD3.

Representative histological stainings for detection of macrophages in general, macrophages with predominantly pro-inflammatory actions, monocytes and T-cells (all green fluorescence) (A-C, E-G, I-K, M-O) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (A-C) Immunofluorescence detection of CSF1R for detection of macrophages in general. (E-G) Immunofluorescence detection of CD86 for detection of macrophages with predominantly pro-inflammatory actions. (I-K) Immunofluorescence detection of CD11b for detection of monocytes. (M-O) Immunofluorescence detection of CD3 for detection of T-cells. Nuclei were stained using DAPI (blue fluorescence). Scale bars: 50 μm. (D,H,L,P) Quantitative analysis of cell infiltration by immunofluorescent staining for CSF1R (D), CD86 (H), CD11b (L) and CD3 (P). All data are expressed as the fluorescence intensity of the marker of interest normalized to the fluorescence intensity of DAPI staining. Values represent means ± SEM; *p < 0.05 vs. control and PCL; +p < 0.05 vs. control and CS-g-PCL.

Immunofluorescence detection of CSF1R, CD86, CD11b and CD3.

Representative histological stainings for detection of macrophages in general, macrophages with predominantly pro-inflammatory actions, monocytes and T-cells (all green fluorescence) (A-C, E-G, I-K, M-O) 14 days after implantation into the dorsal skinfold chamber of BALB/c mice. (A-C) Immunofluorescence detection of CSF1R for detection of macrophages in general. (E-G) Immunofluorescence detection of CD86 for detection of macrophages with predominantly pro-inflammatory actions. (I-K) Immunofluorescence detection of CD11b for detection of monocytes. (M-O) Immunofluorescence detection of CD3 for detection of T-cells. Nuclei were stained using DAPI (blue fluorescence). Scale bars: 50 μm. (D,H,L,P) Quantitative analysis of cell infiltration by immunofluorescent staining for CSF1R (D), CD86 (H), CD11b (L) and CD3 (P). All data are expressed as the fluorescence intensity of the marker of interest normalized to the fluorescence intensity of DAPI staining. Values represent means ± SEM; *p < 0.05 vs. control and PCL; +p < 0.05 vs. control and CS-g-PCL.

Discussion

One of the major challenges in the clinical application of implants is a fast and adequate vascularization of the construct after insertion to guarantee oxygen supply, nutrition of cells and removal of metabolites [10,33]. A lack or delay of angiogenesis and thus supply of nutrients is a common reason for inadequate healing after surgery. Furthermore the poor development of the microcirculation is known as a major problem in the integration of biomaterials [37]. As a consequence, implants should be designed to cause early angiogenesis resulting in a fast vascularization of the implant area and thereby promoting a fast and efficient regeneration. In consideration of these circumstances it is reasonable to test new implant materials with regard to vascularization and biocompatibility. According to current knowledge, the main problem after rotator cuff tear repair is a high prevalence of re-rupture due to variable structural healing [38]. Until now there are only limited options for therapy; in particular there are no implants available, which bridge the defect site and facilitate the repair of tendon-bone-transitions. The critical step in creating a regenerated tendon-bone transition in rotator cuff tear repair is to achieve the functional integration of the implant material in the host tissue during the healing process. The absence of blood vessels in a repairing or metabolically active tissue may inhibit tissue repair; however, the rapid ingrowth of cells and tissues is indispensable regarding the transport of nutrients, waste and oxygen. To analyze microhemodynamic parameters on the muscle tissue over 14 days, the dorsal skinfold chamber is an ideal model. The implant material was tested in this soft tissue-model based on a muscular structure, which allows repeated quantitative assessment of implant vascularization in case of different applications, because the anatomical relationship of the transition between tendon and muscle is readjusted [33,39]. Electrospun fiber mats made of PCL were used for the experimental groups. The biocompatibility of PCL is well known, but its mechanical strength is not sufficient for load bearing applications [40]. Therefore, the electrospinning process was used to produce PCL fiber mats with aligned fibers for higher mechanical strength [25]. As mentioned above the porosity and pore size of the scaffold material is critical for ingrowth of capillaries, therefore based on the decrease in pore size and porosity caused by the modification a reduced vascularization could be anticipated for the CS-g-PCL coated samples. Furthermore chitosan is biocompatible and biodegradable, therefore being well known as a biological material which promotes the healing process of soft and hard tissues [41]. The immobilization of CS-g-PCL on top of electrospun PCL fibers by crystallization resulted in the modification of all fibers also within the material and not only on the surface like other techniques as e.g. plasma treatment [15]. The porous polymer patch, which was used as a control group in this study, has already been tested for biocompatibility [7] and showed an improved outcome in a level IV clinical study after augmentation surgeries [29]. Although the material characteristics of the porous polymer patch differ considerably from that of the experimental groups, this material was selected as a control group as it has already been tested for the application of rotator cuff tear in animal studies and a small retrospective case study [7,29,42]. Before using implant materials for clinical applications, the knowledge about vascularization and biocompatibility is of great importance. Within the groups analyzed in our study we observed different patterns of vascularization. The control group showed a rapid vascularization and a high initial functional capillary density beginning with day three which declined at the next two days and further declined at the end of the observation period. A similar vascularization pattern can be observed during the healing of skin wounds. A histological analysis of this process showed an initially high density of small caliber capillaries. With the ongoing healing of the wound the number of vessels declined and vessel caliber increased [43]. We think that a comparable process accounts for the functional capillary density changes in our control group. Therefore we can conclude, that we observed a fast and complete ingrowth of vascularized tissue in the control scaffold. With respect to the CS-g-PCL group we think that angiogenesis and the growth of the granulation tissue is not that fast as it was observed in the control group and therefore there is still an increase in functional capillary density at the end of the observation period because tissue growth didn’t stopped until that time point. The most important finding in this study was that CS-g-PCL coating improved the vascularization significantly compared to unmodified PCL fiber mats and the porous polymer patch in the long term. The significant increase in functional capillary density in PCL fiber mats with CS-g-PCL modification is a very promising result, especially as in different studies an enhanced vascularization was described as beneficial for the healing of rotator cuff tears. In an experimental study Harada et al. [44] used engineered cell sheets for the repair of resected infraspinatus tendons in rats. After 8 weeks the authors found a significant higher ultimate failure load in the cell sheet group compared the contralateral side which served as control without the implantation of a cell sheet. This enhanced mechanical stability was the result of an improved healing process which based on a higher vascularization of the repair site. An enhanced vascularization may also be beneficial for rotator cuff tear repair in human patients. In a pilot trial Zumstein et al. [45] used athroscopic repair of rotator cuff tears together with leukocyte- and platelet-rich fibrin. This treatment resulted in a higher vascularization six weeks after repair. Fealy et al. [46] also showed an enhanced vascularization immediately after rotator cuff repair by ultrasound imaging. It has to be mentioned that in both studies vascularization decreased at later time points and there were also no differences in clinical parameters at later time points. Nevertheless it seems to be feasible to assume that an enhanced vascularization is beneficial for the early stages of tendon healing after rotator cuff repair. Recent studies demonstrated that vascularization of implants necessitates pores with a diameter of at least 300 μm [47]. Qualitative histologic examinations showed that the porous control polymer patch was well infiltrated with cells 14 days after implantation, because the spongy structure of this scaffold facilitated cell infiltration (but failed to provide mechanical stability). This finding was less apparent in the PCL fiber mats due to the denser structure despite their good biocompatibility. Furthermore, the histologic examinations showed capillaries in the inside of the control group in contrast to the PCL fiber mats, where the vascular structures were entirely limited to the outside of the implants. This result is attributable to the different structures of both materials. While the porous polymer control patch has a porous structure with an interconnected 3D network, which is favorable for cell ingrowth, the PCL fiber mats showed smaller structural spaces due to the aligned fibers [48]. Although the porous polymer patch improved biomechanical stability compared to controls without augmentation, it did not achieve the desired stability of native tendon in biomechanical examinations [7]. An optimal biomaterial should provide a porous texture, which is important for an adequate nutritional supply to the cells and cell-to-cell interactions. Furthermore, the porosity has to be high enough to offer sufficient space for the sprouting of capillaries, cell proliferation, and integration into the surrounding tissue [47]. Therefore further developmental processes are necessary to generate PCL fiber mats that allow a sufficient cellular ingrowth and vascular supply. The modification of PCL with chitosan resulted in an improved in vitro cytocompatibility compared to unmodified PCL [31]. The present study confirmed these data by in vivo data on leukocytes and histological data. In particular, the increase in rolling leukocytes in the PCL group is striking, while the values in the control group and the CS-g-PCL group remain nearly constant. Still, all measured levels for leukocytes are comparatively low in this study [28,35]. In terms of histology the unmodified PCL showed a prominent cellular margin around the implant. However, further characterization of this cell-rich layer around the implant showed only slightly increased numbers of macrophages and neutrophilic granulocytes compared to CS-g-PCL. The immunofluorescences even showed that significant fewer immune cells were detectable in both PCL and CS-g-PCL than in the control group. In terms of biocompatibility these results were promising especially for modified PCL fiber mats, as the porous polymer patch had already been classified as biocompatible in recent studies [32]. With respect to the short observation period, the collagen deposition did not allow any conclusion about a foreign body reaction, although slightly more collagen fibers were detectable in the PCL group. In conclusion our study showed that electrospun PCL fiber mats coated with a CS-graft-PCL copolymer had a significant advantage for vascularization and biocompatibility of the implant in contrast to unmodified PCL fiber mats, even though the porosity and pore size was even smaller after modification with the graft-copolymer compared to unaltered PCL fiber mats. Clinically, these are important findings as they indicate that the modification with chitosan improves the formation of vascularized tissue and the ingrowth of cells. Furthermore the combination of enhanced vascularization and the reduction in immune cell activation at the later time points of our study points to an improved clinical outcome after rotator cuff tear repair. Further investigations should be directed toward enlargement of pore size within the fiber mats during their production to enhance subsequent cell ingrowth. In order to achieve this aim one approach may be to enlarge the remaining space between the aligned fibers, which can be achieved by increasing the fiber diameter [49].

ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines checklist.

(PDF) Click here for additional data file. 23 Sep 2019 PONE-D-19-22863 Vascularization and biocompatibility of poly(ε-caprolactone) fiber mats for rotator cuff tear repair PLOS ONE Dear Dr. Kampmann, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Nov 07 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Feng Zhao Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please complete and submit a copy of the ARRIVE Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://www.nc3rs.org.uk/arrive-guidelines. Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article. Additionally please include the source of the mice used in your study and the minimal information necessary to prepare the electrospun polycaprolactone fiber mats (we note that you have provided a reference but we would recommend including some basic information in this submission). Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The present study shows vascularization of Chitosan grafted PCL scaffolds in dorsal skinfold chamber model. The authors have showed that chitosan grafted PCL significantly improved vascularization compared to unmodified PCL fiber mats and the porous Biomerix patch after 2 weeks of implantation, which can be beneficial for improved tendon repair after tendon injury during rotator cuff tear. Although technically sound, the manuscript requires few corrections as mentioned below. Line: 196 Briefly explain the electrospinning parameters in this section as ref 20 might not be available for everyone. Line 266: briefly mention the method for analyzing: (1) functional capillary density, (2) Number of rolling as well as adherent leukocytes Description regarding Fig 5 (J-L) is missing. Minor comments: Line 422: It Should be “(Figure 6 D, E, F)” instead of (Figure 6 A, B, C). Figure 6 (G, H, I): explain what do you mean by negative control. Is it H&E staining? Figure 7: Please mark the implants (i.e. using #). Reviewer #2: The animal model used lacks relevance in the application specific environment of the proposed treatment. The insight provided by the animal model is useful from a basic standpoint ( of immunogenicity of materials and subsequent vascularization), but cannot be directly linked to rotator cuff injuries and healing progression. The manuscript should be completely revised, centered around the use of the animal model for engineering materials to improve their vascularization and immunogenicity in general, without a specified application. It would be useful for the authors to quantify the results in Fig.7. Fig. 3 needs more explanation. For instance, the control material has a high initial capillary density at days 3 and 10, then decreases. Conversely, the density for the CS-g-PCL material is low initially then suddenly increases. What is the explanation for these two different vascularization patterns? The authors conclude that CS-g-PCL has improved capillary function, based only on one evaluation day out of the four. This would be more convincing if the entire time course was considered. It appears that no statistical test, or the lack of statistical significance is prevelant for the histological data. The authors state that the CS-g-PCL material has reduced immunogenicity, yet there are no statistical differences shown in the graphs or results. Furthermore, the author should explain the reasoning for the post hoc test chosen, among others. The discussion section needs to be better organized. It its rather hard to follow, and makes loose connections between the results and speculated claims. While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. 6 Nov 2019 Reply to the major comments of reviewer 1: 1. A brief description of the electrospinning parameters has been added to the Materials and methods section of our manuscript. A further description seems not to be necessary as reference 20 is an open access publication. Unfortunately reference 20 was not cited correctly in the reference list, we corrected this, so that the information is available for every reader. (see lines 194-200) 2. We added a brief description of the intravital microscopy data analysis to the Materials and Methods section. (see lines 272-286) 3. Figure 5 J-L are negative controls for the immunhistochemical detection of CD31, we added a short description to the respective paragraph of the results section. (see lines 424 and 425) Reply to the minor comments of reviewer 1: 1. Thank you very much or this hint. We corrected the description of figure 6 accordingly. (see lines 443, 444 and 446) 2. As described in the Material and methods section, we performed negative controls be omitting the primary antibody, leaving the rest of the used protocol unchanged. This information is already present in the Materials and methods section of the manuscript, but we also added a short description to the respective paragraph of the results section. (see lines 446-448) 3. As suggested by the reviewer we marked the implants in the microscopic pictures presented in Figure 7 using the same scheme as in Figures 3, 5 and 6. (see updated Figure 7) Reply to the comments of reviewer 2: 1. Our study describes one step in the development process of a new implant for the augmentation of rotator cuff tears. Thereby our research is focused on the vascularization of the implant because this is an important fact, which has considerable impact on the success of the implant. Therefore we don’t agree with the reviewer that our results lack relevance in respect to rotator cuff tears. In different studies an enhanced vascularization was described as beneficial for the healing of rotator cuff tears. In an experimental study Harada et al. [1] used engineered cell sheets for the repair of resected infraspinatus tendons in rats. After 8 weeks the authors found a significant higher ultimate failure load in the cell sheet group compared the contralateral side which served as control without the implantation of a cell sheet. This enhanced mechanical stability was the result of an improved healing process which based on a higher vascularization of the repair site. An enhanced vascularization may also be beneficial for rotator cuff tear repair in human patients. For example Funakoshi et al. [2] showed an increased vascularization of the tendons one or two months after rotator cuff tear repair, which decreased until three months after surgery. In a pilot trial Zumstein et al. [3] used athroscopic repair of rotator cuff tears together with leukocyte- and platelet-rich fibrin. This treatment resulted in a higher vascularization six weeks after repair. Fealy et al. [4] also showed an enhanced vascularization immediately after rotator cuff repair by ultrasound imaging. It has to be mentioned that in both studies vascularization decreased at later time points and there were also no differences in clinical parameters at later time points. Nevertheless it seems to be feasible to assume that an enhanced vascularization is beneficial for the early stages of tendon healing after rotator cuff repair. Therefore we decided to test possible implants for rotator cuff tear repair first in a model that allows the evaluation of vascularization. Implants that were beneficial for vascularization are possible candidates for further research in an animal model of rotator cuff repair. To further enhance our manuscript, we added parts of this argumentation to the discussion section of our manuscript. 2. As suggested by the reviewer we quantified the results in Figure 7 using the software cellSens Dimensions 1.14 (Olympus Deutschland GmbH, Hamburg, Germany). The results of the quantification were added as further information to figure 7. Please refer to our answer to comment 5 for a detailed reply. 3. The different vascularization patterns depicted in Figure 3 can be explained by a different extent of vascular remodeling. The control group showed a rapid vascularization and a high initial functional capillary density beginning with day three. The functional capillary density in the control group showed a decline for the next two days, which was not statistically significant and further declined at the end of the observation period (day 14, statistically significant). A similar vascularization pattern could be observed during the healing of skin wounds. A histological analysis of this process showed an initially high density of small caliber capillaries. With the ongoing healing of the wound the number of vessels declined and vessel caliber increased. [5] We think that a comparable process accounts for the functional capillary density changes in our control group. Therefore we can conclude, that we observed a fast and complete ingrowth of vascularized tissue in the Biomerix scaffold. With respect to the CS-g-PCL group we think that angiogenesis and the growth of the granulation tissue is not that fast as it was observed in the control group and therefore there is still an increase in functional capillary density at the end of the observation period because tissue growth didn’t stopped until that time point. 4. Taken our answer to comment 3 and with respect to the possible clinical application of electrospun fiber mats as scaffolds for the repair of rotator cuff tears we think that the observed changes in functional capillary density are a tolerable, if not desirable feature of such a scaffold. As stated in the answer to comment 1 an enhanced vascularization was described as beneficial for the healing of rotator cuff tears. We therefore think that especially CS-g-PCL fiber mats are well suited for rotator cuff tear repair as they combine a high vascularization with a good biocompatibility. 5. As already stated in our answer to comment 2, we quantified the results of the immunofluorescence detection of macrophages (CD68, CSF1R, CD11b) and T-cells (CD3). Although there were no statistically significant differences for CD11b, the other results supported our hypothesis as they showed a significant lower accumulation of macrophages and T-cells after implantation of PCL and CS-g-PCL implants. We added this new information to the results and discussion section of our manuscript. (see lines 318-324, lines 463-469, lines 481-484, the new Table 4, the new Fig 7 and the related parts of the discussion) 6. We used the Student-Newman-Keuls post-hoc test for differences in means. Once ANOVA gave us statistically significant results, we performed this test to assess which specific pairs of means are different, based on the studenized range distribution. Student-Newman-Keuls is hereby a powerful test and less conservative as other pot hoc tests such as Tukey's range test. We therefore decided to stick to the Student-Newman-Keuls method throughout the whole study. 7. To further enhance the discussion of our manuscript we reorganized the discussion section, thereby adding a discussion of the new information which was added according to the reviewer’s suggestions. References: 1. Harada Y, Mifune Y, Inui A, Sakata R, Muto T, Takase F, Ueda Y, Kataoka T, Kokubu T, Kuroda R, Kurosaka M. Rotator cuff repair using cell sheets derived from human rotator cuff in a rat model. J Orthop Res. 2017 Feb;35(2):289-296. 2. Funakoshi T, Iwasaki N, Kamishima T, Nishida M, Ito Y, Nishida K, Motomiya M, Suenaga N, Minami A. In vivo vascularity alterations in repaired rotator cuffs determined by contrast-enhanced ultrasound. Am J Sports Med. 2011 Dec;39(12):2640-6. 3. Zumstein MA, Rumian A, Lesbats V, Schaer M, Boileau P. Increased vascularization during early healing after biologic augmentation in repair of chronic rotator cuff tears using autologous leukocyte- and platelet-rich fibrin (L-PRF): a prospective randomized controlled pilot trial. J Shoulder Elbow Surg. 2014 Jan;23(1):3-12. 4. Fealy S, Adler RS, Drakos MC, Kelly AM, Allen AA, Cordasco FA, Warren RF, O'Brien SJ. Patterns of vascular and anatomical response after rotator cuff repair. Am J Sports Med. 2006 Jan;34(1):120-7. 5. Johnson KE, Wilgus TA. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv Wound Care (New Rochelle). 2014 Oct 1;3(10):647-661. Submitted filename: Response to Reviewers.docx Click here for additional data file. 17 Dec 2019 PONE-D-19-22863R1 Vascularization and biocompatibility of poly(ε-caprolactone) fiber mats for rotator cuff tear repair PLOS ONE Dear Dr. Kampmann, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Jan 31 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Feng Zhao Academic Editor PLOS ONE Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #3: Authors used the dorsal skinfold chamber model to test the pro-vascularization property of electrospun PCL-based fiber mats. The commercially available porous polyurethane patch (Biomerix™ RCR patch) was used as the control. Both pristine and chitosan-graft-PCL coated electrospun PCL fiber mats were tested. In the chitosan-graft-PCL group at Day 14 vascularization was significantly enhanced, and a reduced activation of immune cells was observed. It is claimed that the CS-g-PCL may benefit the healing of rotator cuff tears by improving the ingrowth of capillaries into electrospun PCL scaffolds and reducing the immune cell activation at the later stage after the implantation. The study was carefully and systematically carried out. However, there are still some minor issues need to be addressed before official publication. 1. The biggest concern is after going through the whole manuscript, the reviewer feels hard to understand why the PCL fiber is specifically beneficial to rotator cuff tear repair. Note that PCL electrospun fiber has been promising for vasculature, bladder, bone, cartilage, and skin tissue engineering. In addition, vascularization and immune response are common issues in all types of tissue engineering. It feels like if rotator cuff tear repair were replaced by vascular tissue repair, the data would still be OK to use. As a result, one suggestion is that in the intro section, detailed background on the use of Biomerix™ RCR patch and PCL specifically for rotator cuff tear or tendon repair should be given, for example in the second paragraph, at Line 180ish. 2. In the paper, authors claim “that the CS-g-PCL improves the ingrowth of capillaries into electrospun PCL scaffolds”. However, the data actually indicate the PCL mats improve the vascularization around not in the implant. Please use more accurate expressions. 3. Experiment section on evaluation of porosity and pore diameter should be re-written. Brief description is needed instead of simply citing other references. 4. Line 251, what do you mean by “in a circular area of 12 mm”? Do you mean “with a diameter of 12 mm?” 5. Table 1, be careful about the significant figures. 0.6594 μm seems meaningless compared with 1.6 μm. Also, be consistent about the significant figures. While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. 19 Dec 2019 Reply to the minor comments of reviewer 3: 1. We thank the reviewer for this suggestion. To better illustrate the reasons why electrospun PCL is well suited for rotator cuff tear repair und to show why we used the specific configuration of the PCL fiber mats, we added additional information, concerning the use of PCL in different tissue engineering application and especially for the repair of rotator cuff tears. Implants for rotator cuff tear repair should have a positive impact on tendon healing by supporting cellular infiltration and guiding the regeneration of an organized tendon structure. By fabrication of fiber mats with directed or undirected fiber orientation they can be adopted to the microarchitecture of the different sections of the native tendon. The specific design of the fiber mat in turn stimulates the regeneration of organized tendon structures. In a previous study we analyzed electrospun PCL fiber mats with undirected fiber orientation, that were intended to mimic the specific fiber orientation at the tendon-bone transition in the femur chamber in rats [Gniesmer et al. 2019]. The current study was designed to examine fiber mats with directed fiber structures, which simulate the tendon-muscle transition. These electrospun PCL fiber mats are intended to form the lead structure for the transition zone of the rotator cuff. (see lines 180-195) 2. We apologies for the confusion caused. The expression “ingrowth of capillaries” was used in the abstract of the manuscript and the conclusion at the end of the discussion section. For a clear discussion of our results we changed the expression to “formation of vascularized tissue and the ingrowth of cells” (see lines 137 and 624) 3. We updated the Materials and methods section and added a brief description how the evaluation of porosity and pore diameter was done. (see lines 227-233) 4. The reviewer is right at this point; by mistake we omitted essential information about the preparation of the observation window. We corrected this mistake in the revised version of the manuscript. (see lines 270 and 271) 5. In the revised version of the manuscript we tried to harmonize the number of digits after the decimal point where possible. In Table 1, 2 and 3 we used one decimal place. In Table 4 the use of three decimal places was necessary and justified by our data. We also corrected wrong use of decimal point and decimal comma in all tables. (see Table 1, 3 and 4) Reference: Gniesmer S, Brehm R, Hoffmann A, de Cassan D, Menzel H, Hoheisel A-L, et al. In vivo analysis of vascularization and biocompatibility of electrospun polycaprolactone fiber mats in the rat femur chamber. J Tissue Eng Regen Med. 2019 Apr 26;0(ja). https://doi.org/10.1002/term.2868 Submitted filename: Response to Reviewers_2.docx Click here for additional data file. 23 Dec 2019 Vascularization and biocompatibility of poly(ε-caprolactone) fiber mats for rotator cuff tear repair PONE-D-19-22863R2 Dear Dr. Kampmann, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Feng Zhao Academic Editor PLOS ONE 3 Jan 2020 PONE-D-19-22863R2 Vascularization and biocompatibility of poly(ε-caprolactone) fiber mats for rotator cuff tear repair Dear Dr. Kampmann: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Feng Zhao Academic Editor PLOS ONE
  45 in total

1.  An aligned 3D neuronal-glial co-culture model for peripheral nerve studies.

Authors:  Muhammad F B Daud; Kiran C Pawar; Frederik Claeyssens; Anthony J Ryan; John W Haycock
Journal:  Biomaterials       Date:  2012-05-30       Impact factor: 12.479

2.  Biomechanical analysis of an ovine rotator cuff repair via porous patch augmentation in a chronic rupture model.

Authors:  Brandon G Santoni; Kirk C McGilvray; Amy S Lyons; Manjula Bansal; A Simon Turner; John D Macgillivray; Struan H Coleman; Christian M Puttlitz
Journal:  Am J Sports Med       Date:  2010-04       Impact factor: 6.202

Review 3.  Vascularization strategies for tissue engineering.

Authors:  Michael Lovett; Kyongbum Lee; Aurelie Edwards; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2009-09       Impact factor: 6.389

4.  Prolongated survival of osteoblast-like cells on biodegradable scaffolds by heat shock preconditioning.

Authors:  Frank Tavassol; Andreas Kampmann; Daniel Lindhorst; Paul Schumann; Horst Kokemüller; Kai-Hendrik Bormann; Nils-Claudius Gellrich; Martin Rücker
Journal:  Tissue Eng Part A       Date:  2011-04-27       Impact factor: 3.845

5.  PCL-TCP wet spun scaffolds carrying antibiotic-loaded microspheres for bone tissue engineering.

Authors:  Elbay Malikmammadov; Tugba Endogan Tanir; Aysel Kiziltay; Vasif Hasirci; Nesrin Hasirci
Journal:  J Biomater Sci Polym Ed       Date:  2017-07-28       Impact factor: 3.517

Review 6.  Strategies to engineer tendon/ligament-to-bone interface: Biomaterials, cells and growth factors.

Authors:  Sonia Font Tellado; Elizabeth R Balmayor; Martijn Van Griensven
Journal:  Adv Drug Deliv Rev       Date:  2015-03-14       Impact factor: 15.470

7.  Electrospun poly(epsilon-caprolactone) microfiber and multilayer nanofiber/microfiber scaffolds: characterization of scaffolds and measurement of cellular infiltration.

Authors:  Quynh P Pham; Upma Sharma; Antonios G Mikos
Journal:  Biomacromolecules       Date:  2006-10       Impact factor: 6.988

8.  Nanofibers prepared by needleless electrospinning technology as scaffolds for wound healing.

Authors:  Michal Dubský; Sárka Kubinová; Jakub Sirc; Luděk Voska; Robert Zajíček; Alena Zajícová; Petr Lesný; Alexandra Jirkovská; Jiří Michálek; Marcela Munzarová; Vladimír Holáň; Eva Syková
Journal:  J Mater Sci Mater Med       Date:  2012-02-14       Impact factor: 3.896

9.  Dorsal skinfold chamber technique for intravital microscopy in nude mice.

Authors:  H A Lehr; M Leunig; M D Menger; D Nolte; K Messmer
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

10.  Fiber-aligned polymer scaffolds for rotator cuff repair in a rat model.

Authors:  David P Beason; Brianne K Connizzo; LeAnn M Dourte; Robert L Mauck; Louis J Soslowsky; David R Steinberg; Joseph Bernstein
Journal:  J Shoulder Elbow Surg       Date:  2012-02       Impact factor: 3.019

View more
  5 in total

1.  Using tools in mechanobiology to repair tendons.

Authors:  Connor C Leek; Jaclyn M Soulas; Anna Lia Sullivan; Megan L Killian
Journal:  Curr Tissue Microenviron Rep       Date:  2021-03-31

2.  Modulating electrospun polycaprolactone scaffold morphology and composition to alter endothelial cell proliferation and angiogenic gene response.

Authors:  James Alexander Reid; Alison McDonald; Anthony Callanan
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

3.  In Situ Characterization of Polycaprolactone Fiber Response to Quasi-Static Tensile Loading in Scanning Electron Microscopy.

Authors:  Alexander Delp; Alexander Becker; Daniel Hülsbusch; Ronja Scholz; Marc Müller; Birgit Glasmacher; Frank Walther
Journal:  Polymers (Basel)       Date:  2021-06-24       Impact factor: 4.329

Review 4.  Next Stage Approach to Tissue Engineering Skeletal Muscle.

Authors:  Gregory Reid; Fabio Magarotto; Anna Marsano; Michela Pozzobon
Journal:  Bioengineering (Basel)       Date:  2020-09-30

5.  Architected fibrous scaffolds for engineering anisotropic tissues.

Authors:  James Alexander Reid; Kiera D Dwyer; Phillip R Schmitt; Arvin H Soepriatna; Kareen Lk Coulombe; Anthony Callanan
Journal:  Biofabrication       Date:  2021-07-27       Impact factor: 9.954

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.